Acute Myeloid Leukemia
Show Only Open Trials
1.
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
- Study Status: Open to Enrollment
- Sponsor: Agios Pharmaceuticals
- Disease Status and/or Stage: Advanced hematologic malignancies
2.
CALGB 100801: Phase II Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older patients With AML
- Study Status: Closed to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Acute Myeloid Leukemia and Myelodysplasia
- Protocol ID: CALGB 100801
3.
Phase III, Multicenter, Randomized, Trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60-75 years of age with untreated high risk (secondary) AML (protocol CLTR0310-301)
- Study Status: Open to Enrollment
- Sponsor: Celator
- Disease Status and/or Stage: Newly Diagnosed High Risk AML, Age 60 to 75
4.
A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Study Status: Closed to Enrollment
- Sponsor: Astellas Pharma
- Disease Status and/or Stage: Relapsed or Refractory Acute Myeloid Leukemia (AML); AC220; ASP2689; blood cancer treatment; Ellen Ritchie; Gail Roboz; Weill Cornell Leukemia: New York Presbyterian Hospital
5.
6.
A Phase Ib Rising Multiple-Dose Clinical Study to Evaluate Safety, Tolerability, and Activity of Oral Monotherapy with KX2-391 in Elderly Subjects with Acute Myeloid Leukemia (AML) Who Are Refractory to or Have Declined Standard Induction Therapy
- Study Status: Closed to Enrollment
- Sponsor: Kinex
- Disease Status and/or Stage: Acute Myeloid Leukemia (AML) in Subjects Age 60 and Older
7.
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
- Study Status: Closed to Enrollment
- Sponsor: Memorial Sloan-Kettering Cancer Center
- Disease Status and/or Stage: Newly Diagnosed Acute Promyelocytic Leukemia
8.
A Randomized study of Combined Haplo-identical Umbilical Cord Transplantation vs. Double Umbilical Cord Transplantation in Patients with Hematologic Malignancies
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
9.
A Prospective Study of Optimally Matched-IPA Targeted Haplo-cord Transplantation
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
10.
BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
- Study Status: Open to Enrollment
- Sponsor: BMT-CTN
- Disease Status and/or Stage: Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People
- Protocol ID: BMT CTN 0903
11.
CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning (RIC) Stem Cell Transplantation Utilizing Double Umbilical Cord Blood (dUCB) Grafts for Patients with Relapsed or Refractory Leukemia
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed/Refractory Leukemia
12.
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Flt3-ITD positive Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: Plexxikon
13.
CALGB 11002 - A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients ≥ 60 Years Old With Acute Myeloid Leukemia (AML)
- Study Status: Closed to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Acute Myeloid Leukemia
14.
Treatment Decision Making in Elderly Patients with Hematological Malignancies: New Approaches to an Old Problem
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematological Malignancies
15.
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
- Study Status: Closed to Enrollment
- Sponsor: Sunesis Pharmaceuticals
- Disease Status and/or Stage: Acute Myeloid Leukemia or Acute Nonlymphocytic Leukemia
16.
A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
- Study Status: Open to Enrollment
- Sponsor: SuperGen
- Disease Status and/or Stage: Intermediate-2 or high-risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
